RULES WERE NOT MEANT FOR THIS BMW. There's a reason the 2 Series is so loved. Blisteringly fast, the 335-horsepower rear-wheel drive M240i Coupe sprints from 0 to 60 mph in just 4.4 seconds, or 4.2 seconds with xDrive, and handles with a steering agility and control that are incredibly precise.
Tecentriq was approved by the U.S. Food and Drug Administration (FDA) for some patients with lung cancer. PUBLISHED: OCTOBER 18, 2016. Be the first to discuss this article on CURE's forum.
Download resources for TECENTRIQÂ® (atezolizumab) non-small cell lung cancer (NSCLC) treatment.. TECENTRIQ INDICATION Metastatic Non-Small Cell Lung Cancer (NSCLC). TECENTRIQ is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.